Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- 2018 Top Stories in Oncology: The Rising Tide of Precision Medicine in Metastatic Breast Cancer
- SABCS 2018: Recommendations From Dr. Reshma Mahtani
- Palbociclib Plus an Aromatase Inhibitor or Fulvestrant for HR+/HER2− Advanced/Metastatic Breast Cancer
- Predictors of Prolonged Benefit With Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant HR+/HER2− Metastatic Breast Cancer
- ESMO 2018: Recommendations From Dr. Reshma Mahtani
- Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer
- First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in HER2+ and HR+ Metastatic or Locally Advanced Breast Cancer
- Meaningful Activity of Poziotinib in HER2+ MBC After ≥2 Prior HER2-Directed Regimens
- Ruxolitinib in Metastatic Triple-Negative Breast Cancer
- Ribociclib Plus Endocrine Therapy for Premenopausal Women With HR+ Advanced Breast Cancer